Back to search

Switzerland· 57266005

Tarceva 150 mg, Filmtabletten

A erlotinib product containing erlotinibum, registered in Switzerland by Cheplapharm Schweiz GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EB02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTarceva 150 mg, FilmtablettenATCL01EB02REGISTER NO.57266005PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Erlotinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EB02 (erlotinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Erlotinib · ATC L01EB02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of erlotinib costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.

  • Switzerland: $102.78 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Erlotinib · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

  • CH Switzerland$102.78
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
erlotinibum
Manufacturer
Cheplapharm Schweiz GmbH
Country
Switzerland (CH)
ATC code
L01EB02
ATC class
Erlotinib
Defined daily dose
0.15 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680572660050
    30 Stk
    CHF 2261.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

355 interactions on record for erlotinib.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Erlotinib · interactions on record

355 records

  • 14 severe
  • 192 moderate
  • 2 minor
  • 147 info

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Erlotinib in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All erlotinib products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Belgium · Erlotinib Sandoz
  • Bulgaria · Ерлотиниб Актавис, Ерлотиниб Крка
  • Cyprus · Erlotinib Remedica
  • Czechia · Erlotinib Krka, Erlotinib Teva
  • Germany · Erlotev, Erlotinib Axiromed
  • Denmark · Erlotinib "stada", Erlotinib Krka
  • Estonia · Erlotinib Viatris
  • Spain · Erlotinib Sandoz, Erlotinib Tarbis
  • Finland · Erlotinib Krka, Erlotinib Stada
  • France · Erlotinib Biogaran, Erlotinib Eg
  • United Kingdom (Northern Ireland) · Erlotinib Amarox, Erlotinib Glenmark
  • Greece · Erlotinib Faran, Erlotinib Teva
  • Croatia · Erlotinib Alpha-Medical, Erlotinib Krka
  • Hungary · Erlotinib Actavis, Erlotinib Krka
  • Iceland · Erlotinib Krka, Erlotinib Teva
  • Italy · Erlotinib Mylan, Erlotinib Sandoz
  • Liechtenstein · Tarceva
  • Lithuania · Erlotinib Viatris, Varlota
  • Latvia · Erlotinib Sandoz, Erlotinib Viatris
  • Netherlands · Erlotinib Accordpharma, Erlotinib Amarox
  • Norway · Erlotinib Krka, Tarceva
  • Poland · Erlotinib Zentiva
  • Portugal · Erlotinib Mylan, Erlotinib Qritou
  • Romania · Erlotinib Krka, Erlotinib Viatris
  • Sweden · Erlotinib Krka, Erlotinib Medical Valley
  • Slovenia · Erlotinib Krka, Erlotinib Teva
  • Slovakia · Erlotinib Sandoz, Erlotinib Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e9cbdf68-722e-4c07-bf31-5a1a19dbc0a9
GET /v1/drugs/e9cbdf68-722e-4c07-bf31-5a1a19dbc0a9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "erlotinibum 150 mg",
  "valid_from": "2005-06-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nZur Behandlung von Patienten mit lokal fortgeschrittenem oder metastasierendem nichtkleinzelligem Lungenkrebs, bei denen mindestens eine vorgängige Chemotherapie wirkungslos geblieben ist.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2007-01-01\"},{\"description\":\"Erstlinienbehandlung und Erhaltungsbehandlung von Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit EGFR-aktivierenden Mutationen.<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2017-01-01\"}]",
  "galenic_form": "Filmtabl 150 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2005-06-01",
  "self_retention_pct": 10
}

See everything about erlotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.